The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome

Acta Neuropathol Commun. 2022 Apr 13;10(1):53. doi: 10.1186/s40478-022-01356-1.

Abstract

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies examining plaque-associated proteins have shown these additional proteins are important; they provide insight into the factors that drive amyloid plaque development and are potential biomarkers or therapeutic targets for Alzheimer's disease (AD). The aim of this study was to comprehensively identify proteins that are enriched in amyloid plaques using unbiased proteomics in two subtypes of early onset AD: sporadic early onset AD (EOAD) and Down Syndrome (DS) with AD. We focused our study on early onset AD as the drivers of the more aggressive pathology development in these cases is unknown and it is unclear whether amyloid-plaque enriched proteins differ between subtypes of early onset AD. Amyloid plaques and neighbouring non-plaque tissue were microdissected from human brain sections using laser capture microdissection and label-free LC-MS was used to quantify the proteins present. 48 proteins were consistently enriched in amyloid plaques in EOAD and DS. Many of these proteins were more significantly enriched in amyloid plaques than Aβ. The most enriched proteins in amyloid plaques in both EOAD and DS were: COL25A1, SMOC1, MDK, NTN1, OLFML3 and HTRA1. Endosomal/lysosomal proteins were particularly highly enriched in amyloid plaques. Fluorescent immunohistochemistry was used to validate the enrichment of four proteins in amyloid plaques (moesin, ezrin, ARL8B and SMOC1) and to compare the amount of total Aβ, Aβ40, Aβ42, phosphorylated Aβ, pyroglutamate Aβ species and oligomeric species in EOAD and DS. These studies showed that phosphorylated Aβ, pyroglutamate Aβ species and SMOC1 were significantly higher in DS plaques, while oligomers were significantly higher in EOAD. Overall, we observed that amyloid plaques in EOAD and DS largely contained the same proteins, however the amount of enrichment of some proteins was different in EOAD and DS. Our study highlights the significant enrichment of many proteins in amyloid plaques, many of which may be potential therapeutic targets and/or biomarkers for AD.

Keywords: Alzheimer’s disease; Amyloid beta; Amyloid plaques; Down syndrome; Early onset; Mass spectrometry; Proteomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides / metabolism
  • Brain / pathology
  • Down Syndrome* / pathology
  • Glycoproteins
  • High-Temperature Requirement A Serine Peptidase 1 / metabolism
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Plaque, Amyloid / pathology
  • Proteome / metabolism
  • Pyrrolidonecarboxylic Acid

Substances

  • Amyloid beta-Peptides
  • Glycoproteins
  • Intercellular Signaling Peptides and Proteins
  • OLFML3 protein, human
  • Proteome
  • High-Temperature Requirement A Serine Peptidase 1
  • HTRA1 protein, human
  • Pyrrolidonecarboxylic Acid